Stay updated with breaking news from Zane Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The BRAF inhibitor AMB-1310 is currently being studied in both the United States and China for the treatment of patients with glioblastoma who are carrying the BRAF V600E mutation.
/PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the...
The FDA has granted fast track designation to ABM-1310 for the treatment of patients with glioblastoma harboring BRAF V600E mutations.
/PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its...
/PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term...